alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Implementation Grant on Liver Transplantation.                    

*Date:*                         August 8, 2022.                    

*Time:*                         9:30 a.m. to 12:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         NIH-NIDDK, 6707 Democracy Blvd., Room 7017, Bethesda, MD 20817 (Virtual Meeting).                    

*Contact Person:*                         Maria E. Davila-Bloom, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7017, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7637,                         *davila-bloomm@extra.niddk.nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: June 28, 2022.

Miguelina Perez, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-14131 Filed 6-30-22; 8:45 am]

BILLING CODE 4140-01-P
An official website of the United States government.								Here's how you know we're official.				

##### dot gov icon**Official websites use .gov**

A **.gov** website belongs to an official government organization in the United States.

##### https icon**Secure websites use HTTPS**

A small lock or **https://** means you’ve safely connected to a .gov website. Share sensitive information only on official, secure websites.

National Ocean ServiceNational Oceanic and Atmospheric Administration

              -  Home 
              -  Ocean Facts 
              -  TOPICS ****                  - Explore All Topics
                - Careers
                - Economy
                - Ecosystems
                - Geodesy
                - Hazards
                - Navigation
                - Observations
                - Ocean
                - Recreation
                - Sea Level Rise 
                - Story Maps
                - Tools 
              -  Education 
              -  News 
              -  Podcasts 
              -  Video 
              -  Images 
              -  About Us 

HomeEducationCoralsCoral Reef Benefits

# Coral Reef Benefits

Healthy coral reefs  contain thousands of fish and invertebrate species found nowhere else  on Earth. They provide millions of dollars to local economies through  tourism and fishing. Many scientists believe that drugs to treat  cancer, arthritis, and other diseases may be found by examining the  unique species that live only in and around reef systems.

### Corals Lessons

              - Welcome
              - What are Corals?
              - Zooxanthellae What's That?
              - How Do Stony Corals Grow?
              - How Do Coral Reefs Form?
              - Where Are Coral Reefs Found?
              - How Do Corals Reproduce?
              - Importance of Coral Reefs
              - Natural Threats to Coral Reefs
              - Anthropogenic Threats to Corals
              - Coral Diseases
              - Protecting Coral Reefs
              - References
              - Roadmap to Resources 
              - Subject Review (PDF)

----

National Science Teaching Association (NSTA)

###### **Search** Education

###### Get **Social**

Contact Us

            - Provide Feedback 
            -  Contact Us 
            -  Report an error 

##### Science. Service.Stewardship.

###### 						About NOS 					

            - About Us
            - NOS Program Offices
            - Media Inquiries
            - Website Acknowledgements

###### 						Resources 					

            - Site Index
            - Disclaimer
            - Freedom of Information Act
            - Accessibility

###### 						More Resources 					

            - Information Quality
            - Privacy Policy
            - NOS For Employees
            - USA.gov

          -  National Ocean Service
          -  National Oceanic and Atmospheric Administration
          -  Department of Commerce

##### 						Social 					

            - 
            - 
            - 
            - 
            -
Exhibit 32.2



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002



In connection with this Annual Report of QuadraMed
Corporation (the Company) on Form 10-K for the period ended December 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Charles J. Stahl, Chief Financial Officer of the Company,
certify pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



2. The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company.



|      |  |                |  |  |  |                                                                                                                
|----- |  | -------------- |  |  |  | ---------------------------------------------------------------------------------------------------------------
|      |  |                | 
|Date: |  | March 15, 2004 |  |  |  | /s/    Charles J. Stahl                                                                                        
|      |  |                |  |  |  |                                                                                                                
|      |  |                |  |  |  | Charles J. Stahl Executive Vice President, Chief
Financial Officer (Principal Financial and Accounting Officer)
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; U24 ATLAS Applications.                    

*Date:*                         July 29, 2022.                    

*Time:*                         1:00 p.m. to 3:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, NIDDK, Democracy II , 6707 Democracy Blvd.,  Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Ryan G. Morris, Ph.D., Scientific Review Officer, Review Branch, Division of Extramural Activities, NIDDK, National Institutes of Health, Room 7015, 6707 Democracy Boulevard Bethesda, MD 20892-2542, 301-594-4721,                         *ryan.morris@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Miguelina Perez, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-13700 Filed 6-27-22; 8:45 am]

BILLING CODE 4140-01-P
```

[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4771 Introduced in House (IH)]

110th CONGRESS
  1st Session
                                H. R. 4771

     To extend the temporary suspension of duty on electric knives.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           December 17, 2007

Mr. Scott of Virginia introduced the following bill; which was referred 
                   to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
     To extend the temporary suspension of duty on electric knives.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ELECTRIC KNIVES.

    (a) In General.--Heading 9902.23.39 of the Harmonized Tariff 
Schedule of the United States is amended by striking ``12/31/2009'' and 
inserting ``12/31/2011''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
**Exhibit 24.1****POWERS OF ATTORNEY**     KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned hereby constitutes and appointsC. Allen Bradley, Jr., Geoffrey R. Banta and Todd Walker, and each of them, the true and lawfulattorney or attorneys-in-fact, with full power of substitution and resubstitution, for him and inhis name, place and stead, to sign on his behalf as a director or officer or both, as the case maybe, of AMERISAFE, Inc. an Annual Report on Form 10-K for the fiscal year ended December 31, 2006under the Securities Exchange Act of 1934, as amended, and to sign any or all amendments theretoand to file the same, with all exhibits thereto, and other documents in connection therewith, withthe Securities and Exchange Commission, granting unto said attorney or attorneys-in-fact, and eachof them with or without the others, full power and authority to do and perform each and every actand thing requisite and necessary to be done in and about the premises, as fully to all intents andpurposes as he might or could in person, hereby ratifying and confirming all that said attorney orattorneys-in-fact or any of them or their substitute or substitutes, may lawfully do or cause to bedone by virtue hereof.   /s/ C. Allen Bradley, Jr.     C. Allen Bradley, Jr. Paul B. Queally   /s/ Geoffrey R. Banta /s/ Sean M. Traynor   Geoffrey R. Banta Sean M. Traynor   /s/ Thomas W. Hallagan /s/ Austin P. Young, III   Thomas W. Hallagan Austin P. Young, III   /s/ Jared A. Morris Jared A. Morris  Dated: February 27, 2007
**Exhibit 32.2****CERTIFICATION PURSUANT TO****18 U.S.C. SECTION 1350,****AS ADOPTED PURSUANT TO****SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**In connection with the Annual Report of Kos Pharmaceuticals, Inc. (the “Company”) on Form 10-K forthe year ending December 31, 2005, as filed with the Securities and Exchange Commission on the datehereof (the “Report”), I, Kevin P. Clarke, Chief Financial Officer of the Company, certify,pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:     (1) The Report fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and     (2) The information contained in the Report fairly presents, in all material respects, thefinancial condition and result of operations of the Company.         /s/ Kevin P. Clarke   Kevin P. Clarke   Chief Financial Officer March 16, 2006 A signed original of this written statement required by Section 906 has been provided to KosPharmaceuticals, Inc. and will be retained by Kos Pharmaceuticals, Inc. and furnished to theSecurities and Exchange Commission or its staff upon request.
Exhibit



Exhibit 10.7
EXECUTION COPY



FIRST AMENDMENT 
TO
 EMPLOYMENT AGREEMENT
May 31, 2019
Whereas, Watford Holdings Ltd., a Bermuda corporation (the “Company”), and Alexandre Scherer (the “Executive”) entered into an employment agreement dated November 18, 2018 (the “Employment Agreement”);
Whereas, Section 12.02 of the Employment Agreement provides that the Company and the Executive may amend the Employment Agreement by written agreement executed and delivered to each party; 
Whereas, the Company and the Executive desire to amend the Employment Agreement as permitted by Section 12.02 thereof;
NOW THEREFORE, the Company and the Executive hereby amend the Employment Agreement as provided herein.
1.    Section 12.09 of the Employment Agreement is hereby amended by adding the following sentence to the end of such Section 12.09: 
Notwithstanding anything to the contrary in this Agreement, all payments or benefits that are due after December 31 of the calendar year following the calendar year in which such payment or benefit vests for purposes of Section 457A of the Code, shall be made or provided on such December 31.    
2.    Except as amended herein, the Employment Agreement shall remain in full force and effect without modification. 
3.     The provisions of this First Amendment to the Employment Agreement may be amended or waived only by a written agreement executed and delivered by the Company and the Executive. No other course of dealing between the parties to this First Amendment to the Employment Agreement or any delay in exercising any rights hereunder will operate as a waiver of any rights of any such parties.
4.    This First Amendment to the Employment Agreement may be executed simultaneously in two counterparts, any one of which need not contain the signatures of more than one party, but all of which counterparts taken together will constitute one and the same agreement. 
6.    ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS AGREEMENT WILL BE GOVERNED BY THE INTERNAL LAW OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICT OF LAWS. 
7.    The parties agree to the nonexclusive jurisdiction of the federal and state courts situated in New York County, New York, for the resolution of any dispute arising under this Agreement or under any share-based award agreements between the Company and the Executive.


-1-





IN WITNESS WHEREOF, the parties hereto have executed this First Amendment to the Employment Agreement as of the date and year first above written.
	
		
	WATFORD HOLDINGS LTD.

	 
	 

	By:
	/s/ John Rathgeber

	 
	Name: John Rathgeber

	 
	Title: Chief Executive Officer

	 
	 

	EXECUTIVE

	 
	 

	By:
	/s/ Alexandre Scherer

	 
	Name: Alexandre Scherer








-2-
<PAGE>   1
                                                                    EXHIBIT 3.3



                             ARTICLES OF AMENDMENT
                                     TO THE
                          ARTICLES OF INCORPORATION OF

                             MEDICAL ALLIANCE, INC.


     Pursuant to the provisions of Article 4.04 of the Texas Business
Corporation Act, the Board of Directors of Medical Alliance, Inc. (the
"Company") adopts the following Articles of Amendment to its Articles of
Incorporation.


                                  ARTICLE ONE

     The name of the corporation is Medical Alliance, Inc.


                                  ARTICLE TWO


     The following Amendment to the Company's Articles of Incorporation was
adopted by a majority of the shareholders of the Company at the Company's Annual
Meeting on the 7th day of December, 2000.  As of that date, 6,119,563 shares
were outstanding, 5,675,081 of which were entitled to vote on the Amendment. Of
the 5,675,081 shares entitled to vote, 4,284,145 shares were voted for, and
28,588 shares were voted against, the Amendment.

     The Amendment alters Article Four of the original Articles of Incorporation
to read as follows:

          The name of the corporation is MAII Holdings, Inc.

     DATED this 14th day of December, 2000.



                                         /s/ MARK NOVY
                                         -------------------------------
                                         Mark Novy, Secretary
Order entered October 3, 2016

In The



## Court of Appeals

Fifth District of Texas at Dallas

No. 05

- 15

- 01014

- CR

KIELLE DROMONE MCNEA L, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the Cri minal District Court No. 5

Dallas County, Texas

Trial Court Cause No. F

- 1500409

- L



### O RDER

We GRANT appellee’s September 30, 2016 “Second Motion to Extend Time for Filing

State’s Brief.” We ORDER the brief tendered to this Court by appellee on September 30, 2016

timely filed as of the date of this order.

/s/ DOUGLAS S. LANG

JUSTICE
_______________________________________ __ Michigan Supreme Court 

# Order

Lansing, Michigan

January 20, 2006 Clifford W. Taylor,
Chief Justice

127834 Michael F. Cavanagh
Elizabeth A. Weaver Marilyn Kelly Maura D. Corrigan MICHIGAN TOOLING ASSOCIATION Robert P. Young, Jr. WORKERS COMPENSA TION FUND, as Stephen J. Markman, Subrogee of DISTEL TOOL & MACHINE Justices COMPANY, Plaintiff-Appellee,

v SC: 127834 COA: 249013 Oakland CC: 2001-030684-CK FARMINGTON INSURANCE AGENCY, LLC,Defendant/Third-Party PlaintiffAppellant, and

MACHINERY MAINTENA NCE SPECIALISTS, INC., Defendant, and

EMPLOYERS INSURANC E OF WAUSAU and WAUSAU INSURANCE COMPANIES, Third-Party Defendants-Appellees.

________________ _______________ __________/

On January 12, 2006, the Court heard oral argument on the application for leave to appeal the December 7, 2004 judgment of the Court of App eals. On order of the Court, the application is again considered. In lieu of granting leave to ap peal, we REVERSE the judgment of the Court of Appeals and REMA ND this case to the Oakland Circuit Court for entry of judgment in favor of F armington Insurance Ag ency, LLC. MCR 7.302(G)(1). Farmington Insurance Agency did not owe a duty to Distel Tool & Machine Company because it could not have reasonably foreseen th at Distel would rely on a
certificate of insurance that wa s issued to another company. In all other respects, the application is DENIED, becau se this disposition renders moot the remaining question presented.

C AVANAGH and K ELLY

, JJ., would deny leave to appeal.

p0117 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

January 20, 2006

Clerk
STATE v. JACKSON.

No. COA03-357.

Court of Appeals of North Carolina.

Filed July 20, 2004.

Certification Date August 9, 2004.

Case reported without published opinion. No error, remanded for correction of clerical error.
<PAGE>   1
                                   EXHIBIT 11
                       CHASE PREFERRED CAPITAL CORPORATION
                       COMPUTATION OF NET INCOME PER SHARE


Net income for basic and fully diluted earnings per share is computed by
subtracting from the applicable earnings the dividend requirements on preferred
stock to arrive at earnings applicable to common stock and dividing this amount
by the weighted average number of common shares outstanding during the period.
<TABLE>
<CAPTION>

                                                                              For the Year             For the Year
(in thousands, except shares outstanding):                                  Ended 12/31/00          Ended 12/31/99
-------------------------------------------------------------------------------------------------------------------
<S>                                                                             <C>                     <C>
Earnings:

Net income                                                                      $    484,350            $    70,127
Less:  preferred stock dividend requirements                                         382,138                 44,550

Net income applicable to common stock                                           $    102,212            $    25,577

Shares:

Average common shares outstanding (a)                                                      1                      1
Basic and fully diluted net income per share: (a)                               $    102,212            $    25,577



</TABLE>


(a)      All common share and per share amounts have been restated to reflect
         the change, effected on December 29, 1998, of the Company's outstanding
         Common Stock from 572,500 shares, par value $300 per share, to one
         share, par value $171,750,000 per share.
STATE v. FOYE.

No. COA04-299.

Court of Appeals of North Carolina.

Filed June 21, 2005.

Certification Date July 11, 2005.

Appeal from the Lenoir (03CRS52173).

Case without published opinion. No error in part, dismissed without prejudice in part.